Literature DB >> 6767840

Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo.

J A Timbrell, J R Mitchell, W R Snodgrass, S D Nelson.   

Abstract

The relationship between the hepatotoxicity and metabolism of isoniazid and its metabolites, acetylisoniazid and acetylhydrazine, has been investigated. Toxic doses of acetylisoniazid and acetylhydrazine, radiolabeled in the acetyl group, were found to bind covalently to liver protein in vivo. This binding was mediated by the microsomal enzyme system as indicated by the effects of pretreatments altering the activity of these enzymes. Metabolic studies revealed that the pretreatments increased the metabolism of the acetylhydrazine moiety of acetyl-labeled acetylisoniazid and of acetylhydrazine itself by the microsomal enzyme system. Pretreatment with the acyl amidase inhibitor, bis-p-nitrophenyl phosphate, inhibited the hydrolysis of acetylisoniazid to isonicotinic acid plus acetylhydrazine and concomitantly decreased the covalent binding of acetyl-labeled acetylisoniazid. The changes in the metabolism of isoniazid, acetylisoniazid and acetylhydrazine effected by various pretreatments paralleled changes in the severity of the hepatic necrosis caused by the compounds. These results strongly suggest that acetylhydrazine is the metabolite responsible for the hepatic necrosis caused by isoniazid and that mirosomal metabolism of acetylhydrazine in vivo leads to the production of a reactive acylating species capable of reacting covalently with tissue macromolecules.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6767840

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes.

Authors:  J P Uetrecht
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

Review 2.  Mechanisms of drug toxicity and relevance to pharmaceutical development.

Authors:  F Peter Guengerich
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

3.  Role of CYP3A in isoniazid metabolism in vivo.

Authors:  Ke Liu; Feng Li; Jie Lu; Zhiwei Gao; Curtis D Klaassen; Xiaochao Ma
Journal:  Drug Metab Pharmacokinet       Date:  2013-10-29       Impact factor: 3.614

4.  Antituberculous therapy in children.

Authors:  V Seth
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

5.  Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid.

Authors:  E Peretti; G Karlaganis; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 7.  Drug hepatotoxicity.

Authors:  J A Timbrell
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

Review 8.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

9.  Protective effects of kaempferol on isoniazid- and rifampicin-induced hepatotoxicity.

Authors:  Tung-Yuan Shih; Ton-Ho Young; Herng-Sheng Lee; Chung-Bao Hsieh; Oliver Yoa-Pu Hu
Journal:  AAPS J       Date:  2013-04-17       Impact factor: 4.009

10.  Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.

Authors:  Imir G Metushi; Corron Sanders; William M Lee; Jack Uetrecht
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.